Public Health England

National Cancer Intelligence Network

The NCIN Service Profiles

Profiles - Rationale

- Service profiles:
  - Benchmark and assess
  - NHS Trust / multi-disciplinary team (MDT) based
  - Assist clinical teams to reflect on outcomes
  - Assist the commissioners of cancer services to
    - *understand the variation across the MDT's (local service) for both patient experience and patient care.*
  - Indicators included have been
    - *discussed with commissioners and MDT's as being important and form the basis for objective dialogue about clinical practice and service delivery.*

Profiles - structure

NCIN / PHE KIT team *(formally Thames Cancer Registry)* co-production

Hosted in the Cancer Commissioning Toolkit –

- Public view – open access
- Professional view - access registration required



www.cancertoolkit.co.uk

What Profiles are there?

- Breast
- Lung
- Colorectal
- Gynaecology
- Upper GI
- Head and Neck
- Sarcoma

What profiles will there be?

- **October**
  - Haematology
  - HPB
- **December**
  - Brain/CNS
  - Urology
  - Skin

Lung Profile

- First Published March 2013, updated March 2014 (problem with HES data), released into public domain
- Data – cancer registry, CWT, NLCA, CPES, HES, Peer Review
- Roughly half indicators generic, half specialist.
- Specialist indicators largely drawn from NLCA
- Indicators incorporate previous Clinical Lines of Enquiry
- A NCIN / Thames Cancer Registry (now London KIT) co-production

What do profiles show?

- Size
- Demographics
- Specialist Team
- Throughput
- Waiting Times
- Practice
- Outcomes and Recovery
- Patient Experience

Profiles…

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate				Trust rate or percentage compared to England			Source	Period
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low-est	Range	High-est		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41		588	NCDR	2010
	2	Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%		80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%		100%	NLCA	2011
Specialist Team	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes							NCPR	2010/11
	15	Peer review: Proportion of peer review indicators met	SA	85%			89%				NCPR	2010/11
	16	Peer review: are there immediate risks? (4)	SA	No							NCPR	2010/11
	17	Peer review: are there serious concerns? (4)	SA	No							NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%		100%	NLCA	2011
Throughput and pathology	19	Number of urgent GP referrals for suspected cancer	406				293	0		853	CWT	2010/11
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%		93%	NLCA	2011
	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%		100%	NLCA	2011
	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%		79%	NLCA	2011
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%		100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%		97%	HES	2011
Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%		100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57		1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40		2.67	NLCA	2011
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7) — % Red	0	n/a				0%		78%	CPES	2011/12
	41	Number of survey questions and % of those questions scoring red and green (7) — % Green		n/a				0%		69%	CPES	2011/12

Profiles… rationale

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate: Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Trust rate or percentage compared to England: Low-est	Range	High-est	Source	Period
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41		588	NCDR	2010
	2	Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
	11	Number a									NLCA	2011
	12	Number a									NLCA	2011
	13	Proportio									NLCA	2011
Specialist Team	14	Peer revie									NCPR	2010/11
	15	Peer revie									NCPR	2010/11
	16	Peer revie									NCPR	2010/11
	17	Peer revie									NCPR	2010/11
	18	Number a									NLCA	2011
Throughput and pathology	19	Number c									CWT	2010/11
	20	Number a									NLCA	2011
	21	Number a									NLCA	2011
	22	Number a									NLCA	2011
	23	Number a									NLCA	2011
	24	Estimatec									HES	2011
Waiting times	25	Q2 2012/									CWT	2012/13 Q2
	26	Q2 2012/									CWT	2012/13 Q2
	27	Urgent GI									CWT	2011/12
	28	Cases tre									CWT	2011/12
	29	Q2 2012/									CWT	2012/13 Q2
Practice	30	No. and p									NLCA	2011
	31	No. and p									NLCA	2011
	32	No. and p									NLCA	2011
	33	No. and pr									NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57		1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40		2.67	NLCA	2011
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7) — % Red	0	n/a				0%		78%	CPES	2011/12
	41	Number of survey questions and % of those questions scoring red and green (7) — % Green		n/a				0%		69%	CPES	2011/12

- **Assess and benchmark a wide range of information at organisation level**
- **Allows a ‘at a glance’ assessment of an organisation**

Profile anatomy



Profile – size and demographics

Section	#	Indicator
Size	G2	Number of newly diagnosed patients per year *
	L1	Number of NLCA patients - lung cancer
	L2	Number of NLCA patients - mesothelioma *
Demographics	G3	Patients (from #G2) aged 70+ *
	G4	Patients (from #G2) with recorded ethnicity *
	G5	Patients (from #G2) with recorded ethnicity which is not White-British *
	G6	Patients (from #G2) who are Income Deprived (1) *
	G7	Male patients (from #G2) *
	L3	Number and proportion of patients (from #L1) with a stage assigned
	L4	Number and proportion of patients, excluding SCLC, with stage I or II assigned
	L5	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned
	L6	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned
	L7	Proportion of patients (from #L1) with a Performance Status assigned

Profile – Specialist team and throughput

Specialist Team	G8	Peer review: Does the specialist team have full membership? (2)
	G9	Peer review: Proportion of peer review indicators met
	G10	Peer review: are there immediate risks? (3)
	G11	Peer review: are there serious concerns? (3)
	LN1	Number and proportion of patients (from #L1) seen by CNS
Throughput	G13	Number of urgent GP referrals for suspected cancer
	L8	Number and proportion of patients (from #L1) with confirmed NSCLC
	L9	Number and proportion of patients (from #L1) with confirmed SCLC
	L10	Number and proportion of patients (from #L1) with confirmed NSCLC who are diagnosed NOS
	L11	Number and proportion of patients (from #L1) with histological confirmation of diagnosis
	G14	Estimated proportion of tumours with emergency presentations [experimental]

Profile - Waiting Times and Practice

Waiting times	G15	Urgent GP referrals for suspected cancer seen within 2 weeks
	G16	Treatment within 62 days of urgent GP referral for suspected cancer
	G17	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]
	G19	First treatment began within 31 days of decision to treat
	G18	Cases treated that are urgent GP referrals for suspected cancer [experimental]
Practice	L12	No. and proportion of patients (from #L1) receiving surgery, chemotherapy and/or radiotherapy
	L13	No. and proportion resected of patients (from #L1) excluding confirmed SCLC
	L14	No. and proportion resected of patients (from #L1) with confirmed NSCLC
	L15	No. and proportion resected of patients (from #L1), excluding confirmed SCLC ,with stage I and II disease
	L16	No. and proportion of patients (from #L1) with confirmed SCLC receiving chemotherapy
	L17	No. and prop. of patients (from #L1) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy

Profile – Outcomes and Recovery + Patient Experience

Outcomes and Recovery	L19	NLCA: Median survival in days and adjusted hazard ratio for mortality
	L20	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year
Patient Experience	G20	Patients surveyed & % reporting always being treated with respect & dignity (5)
	G21	Number of viable survey questions and % of those questions scoring red (6) **
	G22	Number of viable survey questions and % of those questions scoring green (6) **

How should they be used?

- What factors in the indicators may contribute to the picture (eg age, demographics, ethnicity, emergency presentation etc)
- What indicators are outside the national mean
  - Are these a ‘good’ indication or a ‘bad’ indication
- What indicators fall in the ‘statistical significance cannot be assessed’ but would still give cause for concern

How should they be used?

- Always use the whole basket of indicators:
  - Peer Review – what is the percentage compliance, did the team have immediate risk?
  - Patient Experience - is there CNS availability, are the patients treated with dignity and respect
  - Waiting Times - are there problems in the patient pathway?
  - GP referral – is it appropriate?

Specialist Lung profiles?

- Use a profile format to assess and benchmark organisations (?)
- Some challenges:
  - Only include cases referred for surgery?
  - Can we separate local/specialist cases at same provider?
  - Need a good understanding of how the pathway is represented in the data
- What are the important process, clinical and outcome variables?

Going Forward

- Comparison Reports
- Headline Narrative Reports (Mini-profiles)

- Review of indicators
  - Inclusion of new/other data sources (SACT, DIDs, COSD, Clinical Trials)
  - COSD Level 4 Reports
  - Awareness of other developments – new Lung CRG etc